Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes

Abstract The prandial glucose regulator repaglinide has a rapid onset of action, a short half-life and is metabolised mainly by the liver. Here we report the findings of a 10-week, double-blind, parallel, placebo controlled, randomised trial with repaglinide in 25 diet-treated, sulphonylurea-naive patients with Type 2 diabetes. Repaglinide was titrated, based on capillary blood glucose, from 0.5 mg to a maximum of 4 mg, preprandially with breakfast and dinner. After 10 weeks, repaglinide was associated with a decrease in HbA 1c of 2.3%Hb relative to the placebo group ( P =0.018). This reflected a 30% decrease within the repaglinide group from a mean HbA 1c of 7.0 to 4.9%Hb ( P P P P P